Cytek Biosciences (CTKB) CFO exercises shares, surrenders stock for taxes
Rhea-AI Filing Summary
Cytek Biosciences, Inc. (CTKB) reported that Chief Financial Officer William D. McCombe exercised restricted stock units (RSUs) into 35,420 shares of common stock on August 18, 2026, through three RSU awards. In connection with these vestings, 11,904 shares of common stock were withheld and surrendered to Cytek to satisfy tax withholding obligations at a price of $4.67 per share. Each RSU represents a contingent right to receive one share of common stock, and the related awards vest over four years in specified installment schedules tied to May 18, August 18, November 18 and March 10 of various years.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 23,516 shares
Net Buy
9 txns
Insider
McCombe William D.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F3 | 6,320 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F4 | 13,051 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F5 | 16,049 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 6,320 | -- | -- |
| Tax Withholding | Common Stock F2 | 2,111 | $4.67 | $10K |
| Exercise | Common Stock F1 | 13,051 | -- | -- |
| Tax Withholding | Common Stock F2 | 4,392 | $4.67 | $21K |
| Exercise | Common Stock F1 | 16,049 | -- | -- |
| Tax Withholding | Common Stock F2 | 5,401 | $4.67 | $25K |
Holdings After Transaction:
Restricted Stock Units — 409,153 shares (Direct);
Common Stock — 134,693 shares (Direct)
Footnotes (5)
- F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2. Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
- F3. The shares underlying the RSU Award shall vest over 4 years, with 12/48 of the total shares underlying the RSU Award vesting on May 18, 2025; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter.
- F4. The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
- F5. The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Key Figures
Shares acquired via RSU exercises: 35,420 shares
Shares withheld for taxes: 11,904 shares
Tax-withholding share price: $4.67 per share
+3 more
6 metrics
Shares acquired via RSU exercises
35,420 shares
Total underlying shares from three RSU exercises reported on August 18, 2026
Shares withheld for taxes
11,904 shares
Shares surrendered to Cytek to satisfy tax withholding obligations on August 18, 2026
Tax-withholding share price
$4.67 per share
Per‑share value for common stock withheld to pay tax liability
Derivative exercises (count)
3
Number of RSU-related derivative exercises (code M) in this filing
Code F dispositions (count)
3
Number of tax-withholding dispositions of common stock (code F)
Exercise shares detail
6,320; 13,051; 16,049 shares
Underlying common shares for each of the three RSU exercises
Key Terms
Restricted Stock Units, contingent right, tax withholding obligations, vest over 4 years
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit (the "RSU Award") represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the Issuer's common"
tax withholding obligations financial
"to satisfy tax withholding obligations that arose in connection with the vesting"
vest over 4 years financial
"The shares underlying the RSU Award shall vest over 4 years, with 12/48"
FAQ
What did Cytek Biosciences (CTKB) disclose about William D. McCombe’s Form 4 transactions?
Cytek Biosciences disclosed that CFO William D. McCombe exercised restricted stock units into 35,420 shares of common stock on August 18, 2026, with part of the resulting shares withheld to cover tax obligations related to the RSU vesting.
How many restricted stock units did the Cytek (CTKB) CFO exercise?
The Cytek CFO exercised restricted stock units that converted into 35,420 shares of common stock. These exercises were reported under transaction code M as derivative exercises or conversions of RSUs, each RSU representing a contingent right to receive one share.
How do the Cytek (CTKB) RSU awards for the CFO vest over time?
The RSU awards vest over four years in staged installments. Footnotes describe vesting fractions such as 12/48, 2/48, 3/48, and 4/48 of total RSU shares on recurring dates including May 18, August 18, November 18, and March 10 in successive years.
Were the CTKB Form 4 transactions made under a Rule 10b5-1 plan?
The filing’s Rule 10b5‑1 checkbox is not checked, and the footnotes do not state that the transactions were made under a trading plan. The disclosure therefore does not indicate use of a pre‑arranged Rule 10b5‑1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
